Clinical Trial Update: A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) [Phase 2]

View source ↗

Summary

A Phase II study of AZD2171 (cediranib) in stage IV breast cancer has completed, with results posted in December 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD2171 (cediranib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Male Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-12-23